{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:52:12Z","timestamp":1790016732088,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FDA Office of Womens Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pregnant women are at increased risk of thrombotic adverse events. Plasma derived immune globulin (IG) products, which are used in pregnancy for various indications, may contain procoagulant impurity activated coagulation factor XI (FXIa). Procoagulant IG products have been associated with increased thrombogenicity but their effect in pregnancy is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Late pregnant (gestation days 17\u201320) or early lactation (days 1\u20133) and control female mice were treated with IGs supplemented with human FXIa then subjected to ferric chloride (FeCl<jats:sub>3<\/jats:sub>) vessel injury. Occlusion of blood vessel was assessed by recording blood velocity in the femoral vein for 20\u2009min using doppler ultrasound laser imaging. FXIa dose was selected by the ability to increase thrombin generation in mouse plasma in vitro.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>FXIa produced robust thrombin generation in mouse plasma ex vivo. Following FeCl<jats:sub>3<\/jats:sub>injury, pregnant and non-pregnant mice receiving IG\u2009+\u2009FXIa exhibited faster reduction of blood velocity in femoral vein compared to IG alone or untreated controls. In vitro, thrombin generation in plasma samples collected after thrombosis in FXIa-treated animals was elevated and could be reduced by anti-FXI antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggest that intravenously-administered FXIa may contribute to thrombosis at the site of vascular injury in both pregnant and non-pregnant animals.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12959-020-00245-8","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T12:02:44Z","timestamp":1604750564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice"],"prefix":"10.1186","volume":"18","author":[{"given":"Yanqun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yideng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Parunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Despres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Eckhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2509-1781","authenticated-orcid":false,"given":"Mikhail","family":"Ovanesov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi B.","family":"Struble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"issue":"1","key":"245_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bpobgyn.2011.10.003","volume":"26","author":"G Gray","year":"2012","unstructured":"Gray G, Nelson-Piercy C. Thromboembolic disorders in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2012;26(1):53\u201364.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3","key":"245_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/AOG.0b013e3182310c4c","volume":"118","author":"A James","year":"2011","unstructured":"James A. Committee on practice B-O. practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol. 2011;118(3):718\u201329.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"245_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1741826711432117","volume":"20","author":"N Bush","year":"2013","unstructured":"Bush N, Nelson-Piercy C, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M, et al. Myocardial infarction in pregnancy and postpartum in the UK. Eur J Prev Cardiol. 2013;20(1):12\u201320.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"245_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2217\/WHE.11.19","volume":"7","author":"J Tate","year":"2011","unstructured":"Tate J, Bushnell C. Pregnancy and stroke risk in women. Womens Health (Lond). 2011;7(3):363\u201374.","journal-title":"Womens Health (Lond)"},{"issue":"5","key":"245_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/archinte.1991.00400050081016","volume":"151","author":"FA Anderson Jr","year":"1991","unstructured":"Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med. 1991;151(5):933\u20138.","journal-title":"Arch Intern Med"},{"issue":"10","key":"245_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","volume":"143","author":"JA Heit","year":"2005","unstructured":"Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697\u2013706.","journal-title":"Ann Intern Med"},{"issue":"5","key":"245_CR7","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1097\/AOG.0b013e31821769ed","volume":"117","author":"CJ Berg","year":"2011","unstructured":"Berg CJ, Callaghan WM, Henderson Z, Syverson C. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol. 2011;117(5):1230.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"245_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/archinte.164.1.17","volume":"164","author":"SR Kahn","year":"2004","unstructured":"Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004;164(1):17\u201326.","journal-title":"Arch Intern Med"},{"issue":"23 Suppl 1","key":"245_CR9","first-page":"I22","volume":"107","author":"C Kearon","year":"2003","unstructured":"Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I22\u201330.","journal-title":"Circulation."},{"issue":"10","key":"245_CR10","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1111\/j.1538-7836.2011.04468.x","volume":"9","author":"HS Wik","year":"2011","unstructured":"Wik HS, Enden TR, Jacobsen AF, Sandset PM. Long-term quality of life after pregnancy-related deep vein thrombosis and the influence of socioeconomic factors and comorbidity. J Thromb Haemost. 2011;9(10):1931\u20136.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 4","key":"245_CR11","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.jcv.2009.08.017","volume":"46","author":"SP Adler","year":"2009","unstructured":"Adler SP, Nigro G. Findings and conclusions from CMV hyperimmune globulin treatment trials. J Clin Virol. 2009;46(Suppl 4):S54\u20137.","journal-title":"J Clin Virol"},{"issue":"13","key":"245_CR12","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJMoa043337","volume":"353","author":"G Nigro","year":"2005","unstructured":"Nigro G, Adler SP, La Torre R, Best AM. Congenital Cytomegalovirus collaborating G. passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353(13):1350\u201362.","journal-title":"N Engl J Med"},{"key":"245_CR13","first-page":"WMC002002","volume":"2","author":"JRKW Roemisch","year":"2011","unstructured":"Roemisch JRKW, Zoechling A, Kannicht C, Putz M, Kohla G, Schulz P, Pock K, Huber S, Fuchs S, Buchacher A, Krause D, Weinberger J, Rempeters G. Identification of activated FXI as the major biochemical root cause in IVIG batches associated with thromboembolic events analytical and experimental approaches resulting in corrective and preventive measures implemented into the Octagam\u00ae manufacturing process. WebmedCentral Immunotherapy. 2011;2:WMC002002.","journal-title":"WebmedCentral Immunotherapy"},{"issue":"1","key":"245_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1423-0410.2011.01502.x","volume":"102","author":"M Etscheid","year":"2012","unstructured":"Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang. 2012;102(1):40\u20136.","journal-title":"Vox Sang"},{"key":"245_CR15","volume-title":"Voluntary market withdrawal - September 23, 2010 Octagam [Immune Globulin Intravenous (Human)] 5% Liquid Preparation","author":"Letter. Ow. URGENT","year":"2010","unstructured":"Letter. Ow. URGENT: Voluntary market withdrawal - September 23, 2010 Octagam [Immune Globulin Intravenous (Human)] 5% Liquid Preparation 2010."},{"key":"245_CR16","unstructured":"Ovanesov MV, Shibeko AM, Woodle SA, Anderson CM, Hogwood J, Barson H, Gray E, Scott D. Association of Factor XIa with Intravenous Immune Globulin Products Implicated in Thrombotic Adverse Events: Biochemical Root Cause Investigation. J ThrombHaemost. 2011;(9:272. O-TU-039)."},{"issue":"2","key":"245_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0950-3536(96)80068-0","volume":"9","author":"Bolton-Maggs PH","year":"1996","unstructured":"Bolton-Maggs PH. Factor XI deficiency. Baillieres Clin Haematol. 1996;9(2):355\u201368.","journal-title":"Baillieres Clin Haematol"},{"issue":"2","key":"245_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1046\/j.1365-2141.1997.d01-2015.x","volume":"96","author":"EM Richards","year":"1997","unstructured":"Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol. 1997;96(2):293\u20137.","journal-title":"Br J Haematol"},{"issue":"3","key":"245_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1055\/s-0038-1650294","volume":"75","author":"H ten Cate","year":"1996","unstructured":"ten Cate H, Biemond BJ, Levi M, Wuillemin WA, Bauer KA, Barzegar S, et al. Factor XIa induced activation of the intrinsic cascade in vivo. Thromb Haemost. 1996;75(3):445\u20139.","journal-title":"Thromb Haemost"},{"issue":"1","key":"245_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1160\/TH07-08-0499","volume":"99","author":"S Butenas","year":"2008","unstructured":"Butenas S, Undas A, Gissel MT, Szuldrzynski K, Zmudka K, Mann KG. Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost. 2008;99(1):142\u20139.","journal-title":"Thromb Haemost"},{"issue":"3","key":"245_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.thromres.2010.11.005","volume":"127","author":"M Jankowski","year":"2011","unstructured":"Jankowski M, Undas A, Kaczmarek P, Butenas S. Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation. Thromb Res. 2011;127(3):242\u20136.","journal-title":"Thromb Res"},{"issue":"6","key":"245_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MBC.0b013e328346c2bb","volume":"22","author":"J Luszczak","year":"2011","unstructured":"Luszczak J, Undas A, Gissel M, Olszowska M, Butenas S. Activated factor XI and tissue factor in aortic stenosis: links with thrombin generation. Blood Coagul Fibrinolysis. 2011;22(6):473\u20139.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"245_CR23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.20452\/pamw.961","volume":"120","author":"M Zabczyk","year":"2010","unstructured":"Zabczyk M, Butenas S, Palka I, Nessler J, Undas A. Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy. Pol Arch Med Wewn. 2010;120(9):334\u201340.","journal-title":"Pol Arch Med Wewn"},{"issue":"3","key":"245_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/bdrc.21111","volume":"105","author":"E Struble","year":"2015","unstructured":"Struble E, Harrouk W, DeFelice A, Tesfamariam B. Nonclinical aspects of venous thrombosis in pregnancy. Birth Defects Res C Embryo Today. 2015;105(3):190\u2013200.","journal-title":"Birth Defects Res C Embryo Today"},{"issue":"1","key":"245_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-9560-11-12","volume":"11","author":"Y Liang","year":"2013","unstructured":"Liang Y, Woodle SA, Shibeko AM, Lee TK, Ovanesov MV. Correction of microplate location effects improves performance of the thrombin generation test. Thromb J. 2013;11(1):12.","journal-title":"Thromb J"},{"issue":"4","key":"245_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2011-11-393371","volume":"120","author":"AM Shibeko","year":"2012","unstructured":"Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood. 2012;120(4):891\u20139.","journal-title":"Blood."},{"key":"245_CR27","doi-asserted-by":"crossref","unstructured":"Chang WC, Jackson JW, Machlus KR, Wolberg AS, Ovanesov MV. Comparative Analysis of Thrombin Calibration Algorithms and Correction for Thrombin-alpha2macroglobulin Activity. J Clin Med. 2020;9(10).","DOI":"10.3390\/jcm9103077"},{"issue":"12","key":"245_CR28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/ajh.23559","volume":"88","author":"M Menis","year":"2013","unstructured":"Menis M, Sridhar G, Selvam N, Ovanesov MV, Divan HA, Liang Y, et al. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011. Am J Hematol. 2013;88(12):1035\u201340.","journal-title":"Am J Hematol"},{"issue":"11","key":"245_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/1933719111404607","volume":"18","author":"M Phillippe","year":"2011","unstructured":"Phillippe M, Diamond AK, Sweet LM, Oppenheimer KH, Bradley DF. Expression of coagulation-related protein genes during LPS-induced preterm delivery in the pregnant mouse. Reprod Sci. 2011;18(11):1071\u20139.","journal-title":"Reprod Sci"},{"issue":"3","key":"245_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/blood-2007-09-111302","volume":"112","author":"R Sood","year":"2008","unstructured":"Sood R, Sholl L, Isermann B, Zogg M, Coughlin SR, Weiler H. Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. Blood. 2008;112(3):585\u201391.","journal-title":"Blood."},{"issue":"2","key":"245_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1538-7836.2008.03240.x","volume":"7","author":"SN Tchaikovski","year":"2009","unstructured":"Tchaikovski SN, van Vlijmen BJ, Cleuren AC, Thomassen MC, Tchaikovski V, Tans G, et al. Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice. J Thromb Haemost. 2009;7(2):312\u20138.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"245_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1538-7836.2011.04218.x","volume":"9","author":"A Eckly","year":"2011","unstructured":"Eckly A, Hechler B, Freund M, Zerr M, Cazenave JP, Lanza F, et al. Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost. 2011;9(4):779\u201389.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"245_CR33","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1055\/s-0037-1613081","volume":"87","author":"ED Rosen","year":"2002","unstructured":"Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost. 2002;87(4):774\u20136.","journal-title":"Thromb Haemost"},{"issue":"4","key":"245_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","volume":"3","author":"X Wang","year":"2005","unstructured":"Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3(4):695\u2013702.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"245_CR35","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","volume":"4","author":"X Wang","year":"2006","unstructured":"Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006;4(9):1982\u20138.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"245_CR36","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.thromres.2014.09.015","volume":"134","author":"R Loeffen","year":"2014","unstructured":"Loeffen R, van Oerle R, de Groot PG, Waltenberger J, Crijns HJ, Spronk HM, et al. Increased factor XIa levels in patients with a first acute myocardial infarction: the introduction of a new thrombin generation based factor XIa assay. Thromb Res. 2014;134(6):1328\u201334.","journal-title":"Thromb Res"},{"issue":"6","key":"245_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1365-2141.2008.07267.x","volume":"142","author":"JJ van Veen","year":"2008","unstructured":"van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008;142(6):889\u2013903.","journal-title":"Br J Haematol"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-020-00245-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12959-020-00245-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-020-00245-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T02:32:53Z","timestamp":1723861973000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-020-00245-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1186\/s12959-020-00245-8","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,7]]},"assertion":[{"value":"3 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal protocol and procedures within were approved by the FDA Institutional Animal Care and Use Committee (AUCUC) and all methods were performed in accordance with the relevant guidelines and regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors (Y.X., Y.L., L.A.P., D.D., M.E., D.S., M.V.O., and E.B.S.) declare no competing financial interests. This presentation reflects the views of the authors and should not be construed to represent FDA\u2019s views or policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}